MINNEAPOLIS, Oct. 19 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI) announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission in anticipation of a proposed public offering of $10,000,000 (exclusive of over-allotment option) of its common stock.
Craig-Hallum Capital Group and Noble International Investments, Inc will act as underwriters in connection with this proposed public offering. A copy of the prospectus relating to these securities may be obtained, when available, from Craig-Hallum Capital Group, 222 South Sixth Street, Minneapolis, Minnesota 55402.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC(R) system, which we believe is the only FDA-approved non- surgical neurostimulation therapy for the treatment of overactive bladder symptoms. We also offer Macroplastique(R) Implants, a bulking agent for the treatment of urinary incontinence..
The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for certain forward-looking statements. This press release contains
|SOURCE Uroplasty, Inc.|
Copyright©2007 PR Newswire.
All rights reserved